SUBSCRIBE
SUBSCRIBE

RSV

Pictured: Elderly man getting vaccinated by a heal
Policy
RSV Shots May Slightly Raise Risk of Rare Autoimmune Disorder in Older Adults
The FDA and CDC warned Thursday of a small increased risk of developing Guillain-Barré syndrome in older adults after immunization with respiratory syncytial virus vaccines from GSK and Pfizer.
March 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Business
Moderna Posts Surprise Q4 Profit Despite Steep COVID-19 Sales Decline
While COVID vaccine revenue dropped 43% compared to the same period last year, Moderna on Thursday reported a profit of $217 million which beat analyst estimates, driven by deferred payments and cost savings.
February 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
SEKISUI Diagnostics Announces Launch of the OSOM® RSV Test
May 21, 2025
 · 
2 min read
Press Releases
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
April 17, 2025
 · 
9 min read
Press Releases
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
April 17, 2025
 · 
7 min read
Press Releases
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
April 14, 2025
 · 
10 min read
Press Releases
ActivePure’s Advanced Photohydrolysis Technology Demonstrates Rapid Inactivation of SARS-CoV-2, RSV, and Monkeypox Virus in Aerosolized Form
April 1, 2025
 · 
4 min read
Press Releases
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
April 1, 2025
 · 
10 min read
Press Releases
Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium
March 10, 2025
 · 
3 min read
Press Releases
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
February 28, 2025
 · 
4 min read
Press Releases
Inhalon Biopharma Announces First-of-its-Kind Inhaled Antibody Treatment for RSV to Enter Human Clinical Trials
February 3, 2025
 · 
5 min read
Press Releases
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
December 17, 2024
 · 
6 min read
Press Releases
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
December 12, 2024
 · 
5 min read
Press Releases
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
November 21, 2024
 · 
4 min read
Press Releases
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
November 15, 2024
 · 
11 min read
Press Releases
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
November 8, 2024
 · 
5 min read
Press Releases
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
October 24, 2024
 · 
10 min read
Drug Development
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
October 17, 2024
 · 
9 min read
Press Releases
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
October 8, 2024
 · 
10 min read
Press Releases
New American Lung Association RSV Campaign Targets High-Risk Groups Amid Low Vaccination Rates
September 25, 2024
 · 
4 min read
Press Releases
ABRYSVO™: Pfizer Canada’s Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults
September 19, 2024
 · 
6 min read
Press Releases
Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development
August 26, 2024
 · 
4 min read
Load More